Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Trial to Evaluate the Efficacy and Safety of Orally Administered LEO 152020 Tablets Compared With Placebo Tablets for up to 16 Weeks of Treatment in Adults With Moderate to Severe Atopic Dermatitis

NCT05117060 is registered in ClinicalTrials.gov with JW Pharmaceutical as lead sponsor.

NCT NCT05117060
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05117060 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Trial to Evaluate the Efficacy and Safety of Orally Administered LEO 152020 Tablets Compared With Placebo Tablets for up to 16 Weeks of Treatment in Adults With Moderate to Severe Atopic Dermatitis
Lead sponsor
JW Pharmaceutical
Phase
Phase 2
Overall status
Completed
Start date
December 13, 2021
Completion date
July 26, 2023
Enrollment
216 (actual)
Sites
45

Conditions

As the registry lists them; a condition with its own page is linked.

atopic dermatitis